U.S. clinical-stage pharmaceutical company Karuna Therapeutics Inc. has landed a further $12 million as an extension of its Series B financing.

U.S. clinical-stage biopharmaceutical investment firm Sofinnova Investments made the investment which joins existing backers ARCH Venture Partners, Fidelity Management & Research Co. among others.

The new funding brings the total Series B round to $80 million, including the issuance of $5 million in shares upon conversion of debt into equity.

Karuna Therapeutics will use the proceeds to accelerate the development of its lead product KarXT into several new indications, extend the company’s pipeline, and continue to build its infrastructure.